Group 1 - The core viewpoint of the article highlights that Sanofi Pharmaceutical has been awarded the "Hong Kong Stock Value Demonstration Case" for its robust corporate governance and forward-looking innovation strategy, positioning it as a model enterprise in the Hong Kong stock market with both growth potential and investment value [1][2] - The "2025 China Listed Company Yinghua Demonstration Case Selection" aims to promote high-quality development of China's capital market, advocate for value and long-term investment, and contribute to the development of the real economy [1] - The evaluation process involved a comprehensive assessment of A-share and H-share listed companies based on authoritative, objective, and accurate evaluation indicators, with participation from institutional investors managing assets exceeding 50 trillion yuan [1] Group 2 - In 2025, Sanofi Pharmaceutical demonstrated steady performance with accelerated innovation outcomes, achieving breakthrough data in clinical research across core treatment areas such as oncology and autoimmune diseases, alongside significant progress in internationalization and overseas licensing [2] - The company emphasizes its mission of making innovative biopharmaceuticals accessible, continuously increasing investment in research and development, and solidifying the technical strength of its R&D platform, laying a solid foundation for future growth [2] - Sanofi Pharmaceutical currently holds over 100 national invention patents and has more than 40 listed products covering various treatment areas, including nephrology, oncology, autoimmune diseases, ophthalmology, and dermatology [2]
三生制药获“港股价值示范案例”奖